PPI-1011 pre-treatment neuroprotection of striatal dopamine and its metabolites.

<p>Effect of MPTP and PPI-1011 treatment on striatal A) dopamine (DA) contents (<i>F</i>_4,46 = 5.91, <i>p</i> = 0.0006) and its metabolites B) 3,4-dihydroxyphenylacetic acid (DOPAC) (<i>F</i>_4,46 = 6.17, <i>p</i> = 0.0005), C) 3-methoxytyramine (3-MT) (<i>F</i>_4,46 = 3.90, <i>p</i> = 0.008), and D) homovanillic acid (HVA) (<i>F</i>_4,46 = 9.32, <i>p</i> < 0.0001), as well as E) DOPAC/DA (<i>F</i>_4,46 = 1.16, <i>p</i> = 0.34), and F) 3-MT/DA (<i>F</i>_4,46 = 3.03, <i>p</i> = 0.03) and G) HVA/DA (<i>F</i>_4,46 = 3.08, <i>p</i> = 0.02) ratios. Values shown are the means (ng/mg of proteins) ± S.E.M. of 9–12 mice per group. * p < 0.05, ** p < 0.01 and *** p < 0.001 vs control; † p < 0.05, †† p < 0.01, ††† p < 0.001 and †††† p < 0.0001 vs MPTP.